AACR 2023: Integrated platform enables KRAS-targeted drugs discovery

Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as in vivo models resistant to KRAS G12C inhibitors.

4984_Integrated platform enables KRAS-targeted drugs discovery_final - Copy
Related Content
Targeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular...
VIEW RESOURCEThe Son of Sevenless (SOS) protein is a guanine nucleotide exchange factor that acts as a key activator for KRAS...
VIEW RESOURCE